Parkinson'
Conditions
Interventions
[11C]DASB-PET
[11C]DASB-PET
Sponsors
Hamamatsu University School of Medicine
Hamamatsu Photonics KK Hamamatus Medical Photonics Foundation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who agree to discontinue of oral administration of antiparkinson drugs just before examination. 2. Patients who agree to PET examination. 3. Patients with 40 to 75 years of age when obtaining consent. 4. Patients who were obtained consent for this research for himself or herself.
Exclusion criteria
Exclusion criteria: 1. Female patients who are pregnant or planning to become pregnant. 2. Patients with cognitive impairment, aphasia, psychiatric disorders, higher brain dysfunction, suicidal desires, antidepressant drugs. Patients who are taking antidepressant or antipsychotic medications. 3. Patients who are judged by researchers as inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Binding potentials of [11C]N,N dimethyl 2 (2 amino 4 cyanophenylthio)benzylamine ([11C]DASB) PET. Comparison between preoperative bindings and those of six months after surgery. Binding potentials of patients who had operated five to eight years before are also evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| [11C] 2 carbomethoxy 3b (4 fluorophenyl) tropane ( [11C] CFT) PET is also performed for the same patient, and the binding potential is evaluated in the same way. | — |
Countries
Japan
Contacts
Public ContactTakao Nozaki
Hamamatsu University School of Medicine Department of Neurosurgery
Outcome results
None listed